{
  "ticker": "ILA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967683",
  "id": "02967683",
  "pages": 6,
  "price_sensitive": true,
  "date": "20250709",
  "time": "0916",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmmyp3mdr0s8.pdf",
  "summary": "### Summary of Material Information:  \n- **Acquisition of Galidesivir Program**:  \n  - Asset Purchase Agreement signed with BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX).  \n  - Base purchase price: **US$550,000** (includes US$50k option fee).  \n  - Additional milestones:  \n    - US$500k upon Phase 2 completion.  \n    - US$1m upon NDA approval (or US$1.5m if approved via FDA Animal Rule).  \n    - Tiered royalties (5-10% of net sales).  \n    - 25% of proceeds from any Priority Review Voucher (PRV) sale.  \n\n- **Regulatory Pathway**:  \n  - Targeting FDA **Animal Rule** for Marburg indication (potential approval with one additional animal study).  \n  - Potential PRV valued at **US$100\u2013150m** (based on recent transactions).  \n\n- **Funding**:  \n  - Upfront payment and initial Marburg trial funded by existing cash (last reported: **A$4.82m** + A$3.6m placement).  \n\n- **Catalysts**:  \n  - Maiden Marburg animal study expected within **12 months**.  \n\n- **Investor Webinar**:  \n  - Today, 9 July 2025, 11:30am AEST.  \n\n**Key Focus**: Accelerated regulatory path and PRV opportunity significantly de-risk development and enhance valuation upside. Omitted non-material operational/team details.",
  "usage": {
    "prompt_tokens": 3931,
    "completion_tokens": 314,
    "total_tokens": 4245,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:54:16.873183"
}